| Coordinating supply and demand on an on-demand service platform with impatient customers J Bai, KC So, CS Tang, X Chen, H Wang Manufacturing & Service Operations Management 21 (3), 556-570, 2019 | 216* | 2019 |
| A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer LE Minion, J Bai, BJ Monk, LR Keller, EN Ramez, GK Forde, JK Chan, ... Gynecologic oncology 137 (3), 490-496, 2015 | 62 | 2015 |
| Can Two Competing On-Demand Service Platforms be Profitable? J Bai, CS Tang Available at SSRN 3282395, 2018 | 12 | 2018 |
| Evaluating the cost-effectiveness of current FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer. JE Wolford, J Bai, RH Eskander, R Keller, LE Minion, JK Chan, BJ Monk, ... Journal of Clinical Oncology 35 (15_suppl), 5516-5516, 2017 | 9* | 2017 |
| Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma JE Wolford, J Bai, KN Moore, R Kristeleit, BJ Monk, KS Tewari Gynecologic oncology 157 (2), 500-507, 2020 | 8 | 2020 |
| A queueing model for managing small projects under uncertainties J Bai, KC So, C Tang European Journal of Operational Research 253 (3), 777-790, 2016 | 8 | 2016 |
| Comparing Markov and non-Markov alternatives for cost-effectiveness analysis: Insights from a cervical cancer case C del Campo, J Bai, LR Keller Operations Research for Health Care 21, 32-43, 2019 | 5 | 2019 |
| SOLO1 versus SOLO2: Cost-effectiveness of olaparib as maintenance therapy for newly diagnosed and platinum-sensitive recurrent ovarian carcinoma among women with germline BRCA … JE Wolford, KS Tewari, SY Liang, J Bai, AK Mann, KN Moore, ... Journal of Clinical Oncology 37 (15_suppl), 5545-5545, 2019 | 4 | 2019 |
| Markov chain models in practice: a review of low cost software options J Bai, C Del Campo, LR Keller Investigación Operacional 38 (1), 56-62, 2018 | 4* | 2018 |
| Cost-effectiveness of maintenance therapy in advanced ovarian cancer: Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab. JE Wolford, J Bai, LE Minion, R Keller, RN Eskander, JK Chan, BJ Monk, ... Journal of Clinical Oncology 36 (15_suppl), 5508-5508, 2018 | 3 | 2018 |
| Dynamics of a prey-dependent digestive model with state-dependent impulsive control L Qian, Q Lu, J Bai, Z Feng International Journal of Bifurcation and Chaos 22 (04), 1250092, 2012 | 3 | 2012 |
| Challenges in Modelling Time Dependent Transitions in Cost-effectiveness Analysis J Bai, LR Keller, C del Campo Working paper, University of California, Irvine, http://faculty. sites. uci …, 0 | 2 | |
| Time-Based Payout Ratio for Coordinating Supply and Demand on an On-Demand Service Platform J Bai, KC So, CS Tang, XM Chen, H Wang Sharing Economy, 115-136, 2019 | 1 | 2019 |
| Retail Distribution Strategy with Outlet Stores J Bai, H Gurnani, S Yin Available at SSRN, 2019 | | 2019 |
| Interdisciplinary Research in Operations Management: Applications in Healthcare, Retailing and On-demand Service Platforms J Bai UC Irvine, 2017 | | 2017 |
| Optimal Subsidy Schemes and Budget Allocations for Government‐Subsidized Trade‐in Programs J Bai, S Hu, L Gui, KC So, ZJ Ma Production and Operations Management, 0 | | |
Christopher S TangUCLA Distinguished Professor and Edward W. Carter Professor of Business Administrationanderson.ucla.edu üzerinde doğrulanmış e-posta adresine sahip
